Back to Awarded Treatment Trials
Awarded Trial: 11T-002
Investigators conducted a 12-week double-blind, randomized study administering adjunctive treatment consisting of salsalate (4g/day), fluvastatin (40mg/day), and omega-3 fatty acids (700 mg/day EPA, 480 mg/day DHA), versus placebo to 39 participants with schizophrenia with persistent positive symptoms. There was no significant benefit of the combined anti-inflammatory treatment versus placebo on global psychopathology, positive, negative, or depressive symptoms, or cognitive impairment.
Grant ID
11T-002
Illness
Schizophrenia
Primary Drug/Intervention
Salsalate
Primary Dosage
4 g/day
Secondary Drug Intervention
flavastatin
Secondary Dosage
40 mg/day
Other Drug/Intervention
omega-3 (EPA and DHA)
Other Dosage
2 g/day
Status
Completed
Investigator
Buchanan
Sample Size
39
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
N/A
Results
N/A
Publication
N/A
Link
N/A
PI Name
Robert Buchanan
Degree
MD
Center
Maryland Psychiatric Research Center
Institution
N/A
Address
Spring Grove Hospital Grounds, Maple and Locust Streets, PO Box 21247
City or Town
Catonsville
State or Province
MD
Zip or Postal Code
21247
Country
N/A
Email Address
rwbuchanan@mprc.umaryland.edu